NasdaqGS:TXGLife Sciences
10x Genomics Expands Clinical Ambitions As Momentum Outruns Analyst Targets
10x Genomics (NasdaqGS:TXG) announced new collaborations with Brigham & Women's Hospital, Dana-Farber Cancer Institute, and the Cancer Research Institute to apply its single-cell and spatial technologies to autoimmune disease and immuno-oncology research.
The company also launched a multi-year initiative to establish a CLIA-certified laboratory aimed at future clinical applications of its platforms.
For investors watching 10x Genomics, the news comes with the stock at $23.19 and a mixed...